ScreenerHero

LXEOLexeo Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · lexeotx.com
4.880USD-9.12%Mkt Cap: 400.39M $P/E: —

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap400.39M $
Enterprise Value210.24M $
Revenue (TTM)—
Gross Profit-66.64M $
Net Income (TTM)-99.96M $
Revenue/Share—
Last Price4.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.70
PEG—
EV/EBITDA-2.23
EV/Revenue—
P/S—
P/B1.62
EPS (TTM)-0.83
EPS (Forward)-1.37
52W Range
3.99013% of range10.99
52W High10.99 USD
52W Low3.990 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-40.52%
ROA-37.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.56M $
CapEx (TTM)397.00K $
FCF Margin—
FCF Yield-14.68%
Net Debt-204.89M $
Net Debt/EBITDA2.17
Balance Sheet
Debt/Equity0.03
Current Ratio13.89
Quick Ratio13.57
Book Value/Sh3.125 USD
Cash/Share2.580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.30 USD
Upside (mean)+316.0%
Target Range9.000 USD – 30.00 USD
$9.000+316.0% to mean$30.00
# Analysts10
Ownership
Shares Out.82.05M
Float51.24M
Insiders0.58%
Institutions114.27%
Short Interest
Short Ratio18.2d
Short % Float25.53%
Short % Out.21.72%
Shares Short17.05M
Short (prev mo.)16.13M
Technical
SMA 504.693 (+4.0%)
SMA 2006.609 (-26.2%)
Beta1.47
S&P 52W Chg18.16%
Avg Vol (30d)954.65K
Avg Vol (10d)1.02M
Technical Indicators
RSI (14)53.1
MACD0.1006
MACD Signal0.0301
MACD Hist.+0.0705
BB Upper5.251 USD
BB Middle4.638 USD
BB Lower4.024 USD
BB Width26.48%
ATR (14)0.3223 USD
Vol Ratio (20d)0.45x